Novo Nordisk stock gets boost as BofA notes positive oral GLP1 data

Published 07/08/2025, 14:20
© Reuters.

Investing.com - BofA Securities has maintained its Neutral rating and DKK375.00 price target on Novo Nordisk (CSE:NOVOb) (CSE:NOVOB) (NYSE:NVO) following competitor Eli Lilly (NYSE:LLY)’s Phase III oral GLP1 trial results.

The trial data showed Eli Lilly’s oral GLP1 Orforglipron achieved approximately 11% weight loss at 72 weeks in obese patients, which falls below Lilly’s expected 13-14% target and investor expectations.

BofA highlighted that these results compare favorably for Novo Nordisk’s oral Semaglutide 25mg, which demonstrated approximately 14% weight loss and is scheduled for launch in fiscal year 2026, calling it "an underappreciated opportunity."

The bank noted several remaining considerations including supply constraints for oral Semaglutide in higher-priced markets, differences in water/food effects between the competing products, and unclear pricing strategies between Novo Nordisk and Eli Lilly.

Despite the positive comparison to Lilly’s data, BofA maintained its Neutral stance on Novo Nordisk, noting that consensus estimates of approximately DKK3 billion in fiscal year 2026 sales for oral Semaglutide are "likely conservative" while acknowledging unclear short-term growth outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.